Crystalys Secures $130 Million for Gout Drug

Crystalys Therapeutics makes a big move. The company just raised $130 million. This money will help them finish testing a new drug. The drug treats gout. It is called dotinurad.

Gout is a painful type of arthritis. It happens when too much uric acid builds up in the body. Dotinurad helps lower this acid. It could offer relief to many people.

Crystalys will use the funds for final-stage studies. These studies are called Phase 3. They will also get ready to sell the drug if it passes these tests. This funding brings dotinurad closer to patients.

Source: FierceBiotech